FSSAI Clears BMC Ingredients' Rhiza Mycelium Protein for Indian Market
The Food Safety and Standards Authority of India has issued an approval letter for BMC Ingredients' fermented Rhiza Mycelium, clearing commercial use for domestic food processors.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
New Delhi, India — 24 May 2024 — The Food Safety and Standards Authority of India (FSSAI) has issued an official approval letter to BMC Ingredients for Rhiza Mycelium. Produced through the biomass fermentation of Neurospora crassa, the high-protein ingredient is formally authorised for commercial integration into Indian food and nutritional product lines. The clearance directly advances BMC Ingredients’ international distribution network, unlocking commercial entry into one of Asia’s fastest-growing alternative protein markets.
Rhiza Mycelium delivers a whole-food fungal protein matrix harvested from the vegetative mycelial root structures of fungi. BMC Ingredients utilises Neurospora crassa due to its established history of traditional human consumption, a factor that satisfied FSSAI safety assessment criteria. For brand formulators and industrial processors, mycelium provides high protein density combined with dietary fibre, bypassing the intense chemical processing and bitter off-notes frequently associated with isolated pea or soy concentrates.
From a factory floor perspective, fermented fungal biomass exhibits strong water-binding and emulsification capabilities. These functional properties reduce the necessity for auxiliary hydrocolloids and synthetic stabilisers in formulation profiles. Indian food manufacturers targeting ready-to-drink (RTD) beverages, meal replacement powders, and protein bars can deploy the raw material to hedge against dairy commodity price inflation while retaining vegetarian positioning.
What this means for India
FSSAI approval clears Indian brand owners and contract packers to initiate pilot-scale batch trials and negotiate direct volume supply contracts for Rhiza Mycelium. Brands currently manufacturing high-protein foods or RTD beverages should benchmark formulation costs against soy and whey isolates, where local import tariffs and domestic price fluctuations compress gross margins by 8% to 15%. Regulatory leads must verify that finished product labels adhere strictly to FSSAI non-animal novel ingredient standards, ensuring claims reflect whole-food fungal protein rather than traditional single-cell isolates. Manufacturers securing early ingredient allocations can establish differentiated product lines on Indian retail platforms such as Blinkit and Nature's Basket before competitive mass-market adoption.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.